Dalton's GMP oligonucleotide facility ready to roll

Published: 13-Apr-2006

Dalton Pharma Services, a privately-owned Canadian pharmaceutical services provider has completed the commissioning of its new oligonucleotide production suite.


Dalton Pharma Services, a privately-owned Canadian pharmaceutical services provider has completed the commissioning of its new oligonucleotide production suite.

The Toronto-based production suite is equipped with the latest technology for small to large-scale oligo production and purification.


Peter Pekos, Dalton's president and ceo, said: "Large-scale DNA and RNA oligonucleotide synthesis has now gained industry importance with proven therapeutic and diagnostic applications". He added, "With the expansion of our capabilities for the controlled synthesis of multigram quantities of oligonucleotides, Dalton will be able to play a greater role in both diagnostic oligonucleotide manufacturing and antisense therapeutics."

The facility has four AKTA OligoPilots each capable of producing oligos from 500 µmole to 50g scale of oligo per run. Purification is achieved using Waters preparative HPLC's, using either reverse phase or ion-exchange chromatographic techniques. Special controls, including environmental (HEPA filtered air) and manufacturing controls, have also been implemented.

  • Companies:
  • Dalton Pharma Services
See more

You may also like

Manufacturing

3P innovation secures multimillion-pound deal with Dalton Pharma Services for advanced robotic powder filling technology

Read more
Pharmaceutical manufacturing company, Dalton Pharma Services (DPS, a Seikagaku Group company), has recently commissioned 3P innovation (Warwick, UK) to design and construct a fully automated state-of-the-art high-speed aseptic powder filling line to expedite the delivery of drugs to market in a more compliant, efficient and economical manner

Trending Articles

  1. Why CGT manufacturers should automate the production process Cell and gene therapies can be highly complex and time-consuming to produce at scale; full robotic automation could help biologics manufacturers to make processes more space, personnel and cost efficient
  2. IMed Consultancy helps Toby Orthopaedics navigate UK regulations Regulatory consultancy ensures compliance and confidence for Miami-based company
  3. Leybold launches Duradry vacuum pump for harsh processes Advanced technology designed for reliability and efficiency
  4. Pfizer appoints Chris Boshoff as Chief Scientific Officer and President of R&D Dr Boshoff will be responsible for overseeing and advancing Pfizer's R&D initiatives across all therapeutic areas
  5. Anton Paar expands Litesizer DIA Series with new models Introducing affordable and advanced solutions for particle analysis

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Manufacturing

3P innovation secures multimillion-pound deal with Dalton Pharma Services for advanced robotic powder filling technology

Pharmaceutical manufacturing company, Dalton Pharma Services (DPS, a Seikagaku Group company), has recently commissioned 3P innovation (Warwick, UK) to design and construct a fully automated state-of-the-art high-speed aseptic powder filling line to expedite the delivery of drugs to market in a more compliant, efficient and economical manner
Ingredients

Tetra Bio-Pharma engages Dalton Pharma for GMP manufacturing

Tetra Bio-Pharma has awarded the contract for the manufacturing of its active pharmaceutical ingredient ARDS-003
Manufacturing

Dalton expands sterile fill/finish capabilities

The Toronto-based pharma services company said investment is part of a US$10m facility and capital expansion
Manufacturing

Dalton Pharma Services completes $5 million expansion

The project was supported by CA$2.085 million of funding from FedDev Ontario
Manufacturing

Lonza and Dalton to provide integrated chemistry services

Dalton adds geographic diversification to Lonza facilities network
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

The new fight against diabetes and obesity

Incretin mimetics administered by autoinjectors or pens enable significant weight reduction and offer an important way to combat obesity and prevent type 2 diabetes. As such, pharmaceutical manufacturers are currently investing heavily in development and production
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Subscribe now